Ben Braun, MD, PhD
Education
M.D., 1998 - School of Medicine, University of California Los Angeles
Websites
Publications
- Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
- The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
- KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.
- Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.
- Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
- Tissue-Specific Oncogenic Activity of KRASA146T.
- Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
- Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
- A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
- Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
- Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
- Traxtile: Interactive editing of cell tracks in time-lapse images.
- Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
- PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
- Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
- KIT's ship comes in.
- Targeting oncogenic Ras signaling in hematologic malignancies.
- A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
- Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.
- Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
- Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
- Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
- The SPS affair: a complex tale of illicit proliferation.
- JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.
- Oncogenic Kras initiates leukemia in hematopoietic stem cells.
- Pediatric malignancies: update on sarcomas and leukemia development in children.
- Targeting Ras in myeloid leukemias.
- K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
- Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
- Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
- Congenital leukemia cutis with subsequent development of leukemia.
- The sum is greater than the FGFR1 partner.
- Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.
- Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
- EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.
- EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.
- Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis.
- A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
- Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
- The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.
- Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.
- Creation of a yeast artificial chromosome fragmentation vector based on lysine-2.